Lymphoma Clinical Trials: How Subtype and Treatment History Shape Eligibility

Hodgkin and non-Hodgkin lymphoma are not interchangeable

Classic Hodgkin lymphoma has a different biology and treatment pathway from most non-Hodgkin lymphomas. Treatment may include chemotherapy, sometimes with radiation, immunotherapy, or targeted treatment. Trials may study initial treatment or treatment after relapse. Nodular lymphocyte-predominant disease is a distinct diagnosis with a different treatment pathway; it should not be assumed to fit a classic Hodgkin protocol.

Non-Hodgkin lymphoma is an umbrella term. DLBCL is an aggressive B-cell lymphoma. Follicular lymphoma usually grows more slowly. Mantle cell lymphoma has its own treatment pathway. T-cell lymphomas are a separate group and are not interchangeable with B-cell disease in trial listings.

Some slow-growing lymphomas without symptoms can be managed with active surveillance rather than immediate treatment. That is not a general rule for lymphoma: aggressive disease may need prompt treatment. Discuss trial timing with the hematologist rather than delaying recommended care while searching.

Studies of treatment after relapse may distinguish between people who have had one previous treatment and those who have had several. A previous transplant or CAR T-cell treatment may be required in one study and excluded in another.

The plain-language clinical trial glossary can help with terms such as refractory disease, eligibility, and standard of care.

Biopsy findings and biomarkers that separate one trial from another

The full pathology report is the starting point. It identifies the lymphoma subtype using the appearance of the cells and tests for their proteins or gene changes. A specialist review may be needed before a study confirms the diagnosis.

CD20 is a protein found on many B-cell lymphomas and is a target of antibody treatments. CD19 is another B-cell target used in some CAR T-cell therapies. A study may specify a target, a test result, or previous treatment directed at that target. B-cell treatment trials should not be assumed to fit T-cell lymphoma.

CD30 is relevant in classic Hodgkin lymphoma and some non-Hodgkin lymphomas, including anaplastic large cell lymphoma. It is the target of treatments such as brentuximab vedotin. Whether a study requires a CD30 result depends on the protocol.

In certain aggressive B-cell lymphomas, testing for rearrangements involving MYC, BCL2, and sometimes BCL6 helps refine the diagnosis. A gene rearrangement is not the same as increased protein expression. If a report says "double hit" or "double expressor," ask the hematologist what the actual test showed and which diagnosis is being used.

PET-CT results, disease sites, blood tests, and previous response to treatment also matter. These are not all biomarkers, but they can affect eligibility. There is no single test panel that makes someone eligible for every lymphoma trial.

Some treatments mentioned here are already approved in defined settings. Availability depends on the subtype, previous treatment, and the country where care is given. CAR T-cell therapy, for example, is not always experimental; a trial may be studying a new product or a new use of an existing approach.

Recruiting lymphoma trials

Start with the exact diagnosis from the biopsy report, then check the study's criteria for previous treatment. A listing that includes "lymphoma" may still accept only a particular subtype or treatment history. Confirm eligibility and local recruitment with the study team.

Open the full TrialFinder search for lymphoma.

Questions to ask a hematologist

A short list is usually enough:

• What is the exact lymphoma subtype on the pathology report? Is it classic Hodgkin lymphoma, a B-cell lymphoma, or a T-cell lymphoma?
• Does the biopsy need a specialist review or additional testing? Which protein markers or gene changes matter for this diagnosis?
• What is the stage, and is the disease newly diagnosed, relapsed, or refractory?
• Which treatments have already been used, how did the lymphoma respond, and does a previous transplant or CAR T-cell treatment affect the options?
• For this diagnosis and treatment history, what is approved or considered standard where I live? Would looking for a trial delay treatment that should start now?
• Are there recruiting trials that match this exact profile, and how do their treatment, risks, and visit schedule differ from standard care?

Want to prepare for the appointment? The guide How to Talk to Your Doctor About Clinical Trials explains how to raise the topic and what to bring with you.

Sources

• NCI: Lymphoma
• NCI PDQ: Hodgkin lymphoma treatment (patient)
• NCI PDQ: Non-Hodgkin lymphoma treatment (patient)
• NCI PDQ: Aggressive B-cell non-Hodgkin lymphoma treatment (health professional)
• NCI: Biomarker testing for cancer treatment
• NCI: Example of a CD19/CD20-targeted CAR T-cell study
• Study eligibility and recruitment information should be checked against the individual record on ClinicalTrials.gov and confirmed with the study team.

This article was written by a patient advocate based on personal experience, not by a medical professional. It is not medical advice. Consult your doctor before making any medical decisions.